Overview A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) Status: Completed Trial end date: 2005-09-01 Target enrollment: Participant gender: Summary The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome. Phase: Phase 3 Details Lead Sponsor: Astellas Pharma IncTreatments: Solifenacin Succinate